UNSPSC 85816313: Introduction of glucarpidase into peripheral vein, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of glucarpidase into peripheral vein, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E033GQ

UNSPSC 85816313, Introduction of glucarpidase into peripheral vein, percutaneous approach, is a Commodity code with limited recent activity aligned to its clinical specificity. The code nominal scope describes a single intravenous pharmaceutical intervention—glucarpidase administration for methotrexate toxicity—yet the recent state and local opportunities tagged to this code reflect a broader healthcare procurement landscape spanning telehealth platforms, occupational health services, mental health and substance use treatment, emergency medical services, cancer screening, dental services, and related health system operations. None of the recent solicitations explicitly reference glucarpidase or the specific clinical procedure named in the code.

The issuing bodies span multiple state and local jurisdictions: state health authorities (Nevada, Colorado, Texas, New Jersey), county governments and health systems (Inland Empire, DeKalb, San Mateo, Brevard, Santa Clara, Sarasota, Seminole, Forsyth, Solano), municipal agencies (City of Phoenix, City of Atlanta, City of Ocala, City of Rockland), school districts (Parkway), special districts (Events DC, H-GAC cooperative), and regional health networks. Recent opportunities cluster in California (Inland Empire, San Mateo), Nevada (statewide), Georgia (DeKalb, Forsyth, Cobb), Colorado (statewide), Texas (multiple facilities and Houston-Galveston Area Council), and Florida (Brevard, Sarasota, Seminole). The code shows no recent procurement activity for the glucarpidase procedure itself; instead, opportunities under this code appear to reflect a data-tagging mismatch or administrative classification error by issuing bodies. State and local procurement under this code lacks meaningful signal for business development focused on the stated clinical intervention.